EU-GMP Inspection, 2013

On 19 March 2013, the third EU-GMP Inspection was conducted in five continuous days at STADA – VN J.V. Co., Ltd., Binh Duong Branch (the “Company” or “Factory II“), located at Vietnam – Singapore Industrial Park, Binh Duong and the Factory II was recognized as a pharma facility complying with European Good Manufacturing Practice issued by European Medicines Agency, Germany (the “EMA“).

Since 6 years from the date the Factory II has been officially run the operation, the Factory II has continuously recognized as European standard pharmaceutical facility. This is the collective pride of its company’s employees and this proves that we maintain product quality inherent.

It was really a pleasure for us to maintain and observe the right to export the products to foreign markets such as Europe, England, Australia, etc. and some countries complying PIC Convention (Pharmaceutical Inspection Convention).

With this achievement, the company will  be increasingly relentless determination to improve our infrastructure, and investment in machinery, equipment, technology, and qualified personnel as well, etc. to produce and provide high-quality products for the domestic and export activities.


STELLAPHARM is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, anti-viral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An Town, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: | W:

You May like

01 Oct 2021

Merck says research shows its COVID-19 pill works against variants

Sept 29 (Reuters) – Laboratory studies show that Merck & Co’s (MRK.N) experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, including the dominant, highly transmissible Delta, the company said on Wednesday. Since molnupiravir does not target the spike protein of the virus – the target of

27 Apr 2020

Stellapharm supports European partners in Covid-19 pandemic

Since the beginning of February this year, many consignments of Stella’s pharmaceutical products with a total of nearly 200 million units have been urgently exported by air to markets in Germany, France, Austria, Belgium, Ireland, etc.